U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H37N3O4.C4H4O4
Molecular Weight 571.6618
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MOXILUBANT MALEATE

SMILES

OC(=O)\C=C/C(O)=O.COC1=CC(=CC=C1OCCCCCOC2=CC=C(C=C2)C(N)=N)C(=O)N(C(C)C)C(C)C

InChI

InChIKey=BUMMZWFWCNQFPS-BTJKTKAUSA-N
InChI=1S/C26H37N3O4.C4H4O4/c1-18(2)29(19(3)4)26(30)21-11-14-23(24(17-21)31-5)33-16-8-6-7-15-32-22-12-9-20(10-13-22)25(27)28;5-3(6)1-2-4(7)8/h9-14,17-19H,6-8,15-16H2,1-5H3,(H3,27,28);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C26H37N3O4
Molecular Weight 455.5897
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Moxilubant is an orally active leukotriene B4 antagonist patented by Ciba-Geigy A.-G. and studied for psoriasis, rheumatoid arthritis, and chronic obstructive pulmonary disease treatment. Moxilubant inhibits LTB4 signaling with a potency of 2–4 nM. In a phase 1 study in 10 healthy volunteers, Moxilubant was administered orally once or twice daily for 7 days at doses ranging from 100 to 500 mg. At dose levels of 150 mg and above, LTB4 pathway inhibition reached at least 75%. At doses of 300 mg and above, pathway inhibition reached 100%. A Phase 2 study was conducted in 24 patients with COPD treated with 240 mg/day Moxilubant for 4 weeks. In this study, there were no changes in sputum cell counts or biomarkers or in spirometry measures, even though plasma levels of Moxilubant were sufficient to significantly reduce pathway signaling.

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Recent advances in clinical development of leukotriene B4 pathway drugs.
2017 Oct
Patents

Patents

Sample Use Guides

In Vivo Use Guide
300 mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Tue Oct 22 05:43:07 UTC 2019
Edited
by admin
on Tue Oct 22 05:43:07 UTC 2019
Record UNII
PDY6PVU0RB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXILUBANT MALEATE
USAN  
USAN  
Official Name English
CGS-25019C
Code English
CGS 25019C
Code English
MOXILUBANT MALEATE [USAN]
Common Name English
4-((5-(P-AMIDINOPHENOXY)PENTYL)OXY)-N,N-DIISOPROPYL-3-METHOXYBENZAMIDE MALEATE (1:1)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C308
Created by admin on Tue Oct 22 05:43:07 UTC 2019 , Edited by admin on Tue Oct 22 05:43:07 UTC 2019
Code System Code Type Description
PUBCHEM
9959759
Created by admin on Tue Oct 22 05:43:07 UTC 2019 , Edited by admin on Tue Oct 22 05:43:07 UTC 2019
PRIMARY
NCI_THESAURUS
C90813
Created by admin on Tue Oct 22 05:43:07 UTC 2019 , Edited by admin on Tue Oct 22 05:43:07 UTC 2019
PRIMARY
CAS
147398-01-4
Created by admin on Tue Oct 22 05:43:07 UTC 2019 , Edited by admin on Tue Oct 22 05:43:07 UTC 2019
PRIMARY
ChEMBL
CHEMBL89326
Created by admin on Tue Oct 22 05:43:07 UTC 2019 , Edited by admin on Tue Oct 22 05:43:07 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY